NFKB1 and atherosclerosis: This is in agreement with the anti-inflammatory effects of PTL, which was found to be mediated through the inhibition of NF-κB expression in a cisplatin-induced renal damage rat model [21] and in animal models of different diseases, including type 2 diabetes [71], atherosclerosis [72], colitis [73,74], pulmonary fibrosis [75], and myocardial injury [76].